[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor]

Bull Cancer. 2021 Feb;108(2):142-144. doi: 10.1016/j.bulcan.2020.12.006. Epub 2021 Jan 30.

[Article in French]

Authors

Adrien Rousseau¹, Catherine Thieblemont²

Affiliations

¹ AERIO; Association pour l'Enseignement et la Recherche des Internes d'Oncologie, 149, avenue du Maine, 75014 Paris, France. Electronic address: adrien.rousseau45@gmail.com.
² Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, 1, avenue Claude Vellefaux, 75010 Paris, France.

PMID: 33531153
DOI: 10.1016/j.bulcan.2020.12.006

No abstract available

Keywords: BTK inhibitor; CAR T-cell; CD-19; Inhibiteur de BTK; Lymphome à cellules du manteau; mantle cell lymphoma.

Publication types

Letter

MeSH terms

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
Antigens, CD19
Clinical Trials, Phase II as Topic
Drug Approval
Europe
Humans
Immunotherapy, Adoptive / methods
Lymphoma, Mantle-Cell / drug therapy*

Substances

Antigens, CD19
CD19 molecule, human
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human